St. Jude Medical has received CE mark clearance for its quadripolar device, the Quadra Assura MP cardiac resynchronisation therapy defibrillator (CRT-D).
The Quadra Assura MP CRT-D, which is based on the company’s Quadripolar Pacing System, features MultiPoint Pacing (MPP) technology that allows physicians to pace the multiple locations on the left side of the heart.
This offers clinicians more options to best optimise cardiac resynchronisation therapy (CRT) pacing to meet individual patient needs.
The Quadra Assura MP CRT-D is designed to work with the Quartet Lead, which features four electrodes to offer maximum flexibility for various pacing configurations.
The new MPP capability enables physicians to programme simultaneous or sequential delivery of two left ventricular (LV) pulses per pacing cycle, instead of standard single pacing pulse.
The capability to provide two LV pulses per cycle allows physicians to customise CRT pacing for each patient, thereby resulting in more effective outcomes compared to single site pacing.
This method may be particularly beneficial in patients not responding to traditional bi-ventricular pacing therapy.
CRT pacing can be delivered by an implantable cardioverter defibrillator (ICD) to resynchronise the beating of the heart’s lower chambers (ventricles) that usually beat out of sync in heart failure patients.
According to studies, CRT can improve the quality of life for many patients with heart failure, a progressive condition where the heart weakens and loses its ability to pump an adequate supply of blood.
St. Jude Medical Implantable Electronic Systems Division president Eric Fain said that Quadripolar pacing has become the standard of care to many physicians.
"We are pleased to continue our innovation by offering the industry’s first MultiPoint Pacing system, which provides a new set of non-invasive tools to address patients who are non-responders to traditional CRT pacing, potentially decreasing heart failure hospitalizations and lowering the economic burden," Fain added.
Preliminary results from a study presented at the Heart Rhythm Society (HRS) Scientific Sessions in 2013 showed that after three months, 89% of patients treated with the St. Jude Medical MPP were classified as responders, which represents a near 20% increase over the response rate in traditional CRT.
Quadra Assura MP CRT-D is an investigational device in the US, which is not commercially approved in the country.
Image: Quadra Assura MP CRT-D. Photo courtesy of St. Jude Medical.